Clinical practice of immunosuppressive treatments in multiple sclerosis: results of a second international questionnaire.
Immunosuppressive treatment is a current practice in MS therapy. Mitoxantrone has gained largest acceptance. Differences in clinical indications of mitoxantrone, cyclophosphamide, azathioprine and methotrexate are described.
Hommes
O R
OR
European Charcot Foundation, 6533 PA Nijmegen, The Netherlands. info@charcot-ms.org
Weiner
H L
HL
D001379:Azathioprine / Q000627:therapeutic use; D002170:Canada; D002986:Clinical Trials as Topic / Q000706:statistics & numerical data / Q000639:trends; D003520:Cyclophosphamide / Q000627:therapeutic use; D005060:Europe; D006801:Humans; D007166:Immunosuppressive Agents / Q000627:therapeutic use*; D007167:Immunotherapy / Q000379:methods* / Q000639:trends*; D007391:International Cooperation; D008727:Methotrexate / Q000627:therapeutic use; D008942:Mitoxantrone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000188:drug therapy*; D010818:Practice Patterns, Physicians' / Q000706:statistics & numerical data*; D012537:Scandinavian and Nordic Countries; D013020:South America; D011795:Surveys and Questionnaires; D006113:United Kingdom; D014481:United States
D007166:Immunosuppressive Agents; D003520:Cyclophosphamide; D008942:Mitoxantrone; D001379:Azathioprine; D008727:Methotrexate